Business
Placing & First Day of Dealings
Placing & First Day of Dealings.
About this update from Iconic Labs Plc
[{"type":"text","content":"\n \nRNS Number : 3051F WideCells Group PLC 27 July 2016 \n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND, SINGAPORE, HONG KONG OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION\n \n27 July 2016\nWideCells Group PLC ('WideCells Group' or 'the Group')\n£2m Placing, Admission to Trading and First Day of Dealings\n \nWideCells Group, the health care services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment, is pleased to announce that the entire issued share capital of 54,058,061 ordinary shares of 0.25p each ('Ordinary Shares') will today be admitted to the Standard Listing segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange (together 'Admission'). The Company will be trading under the ticker symbol WDC with the ISIN number GB00BD060S65. \n \nHighlights\n· £2 million raised via a placing, conducted by Vicarage Capital Ltd and Shard Capital Partners, of 18,181,819 ordinary shares at 11p per share \n \n· Funds raised are intended to build an integrated stem cell services company, focused on promoting stem cell treatments by making them accessible and affordable\n \n· The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine\n \n· The Group is developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry\n \n· An experienced senior management team that has been integral to the development of its growth and business to date\no CEO, João Andrade, COO Lopes Gil and CSO Dr Peter Hollands have between them over 30 years' senior level experience in the stem cell market\no Further strengthened by the appointment as a non-executive director of Dr Marilyn Orcharton, a qualified dentist ...